{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:14:56Z","timestamp":1791404096643,"version":"4.3.3"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.drudis.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T12:22:04Z","timestamp":1552479724000},"page":"1059-1065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing"],"prefix":"10.1016","volume":"24","author":[{"given":"Katarzyna","family":"Regulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0142osz","family":"Regulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Karolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-7039","authenticated-orcid":false,"given":"Beata","family":"Stanisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.03.010_bib0005","series-title":"Key Facts: What Causes Cancer?","author":"WHO","year":"2018"},{"key":"10.1016\/j.drudis.2019.03.010_bib0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(15)60635-3","article-title":"Cancer and cardiovascular disease: more tightly linked than by chance","volume":"385","author":"Opie","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.03.010_bib0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drudis.2019.03.010_bib0020","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2019.03.010_bib0025","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.2174\/13816128113199990508","article-title":"The renin-angiotensin system as a target of novel anticancer therapy","volume":"19","author":"Regulska","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drudis.2019.03.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2019.03.010_bib0035","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"13","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.03.010_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.03.010_bib0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.06.028","article-title":"ACE inhibitors may reduce esophageal cancer incidence","volume":"131","author":"Lang","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2019.03.010_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jch.12228","article-title":"Lowered cancer risk with ACE inhibitors\/ARBs: a population-based cohort study","volume":"16","author":"Chiang","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.drudis.2019.03.010_bib0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-018-4292-y","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study","volume":"18","author":"Ho","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2019.03.010_bib0060","series-title":"FDA Drug Safety Communication: No Increase in Risk of Cancer with Certain Blood Pressure Drugs \u2013 Angiotensin: Facts about Angiotensin Receptor Blockers","author":"FDA","year":"2011"},{"key":"10.1016\/j.drudis.2019.03.010_bib0065","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2019.03.010_bib0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2017.35.4_suppl.386","article-title":"TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): preliminary feasibility and R0 resection rates from a prospective phase II study","volume":"35","author":"Murphy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","article-title":"Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?","volume":"138","author":"Happold","year":"2018","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc3978","article-title":"Sympathetic nervous system regulation of the tumour microenvironment","volume":"15","author":"Cole","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2019.03.010_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.11.007","article-title":"\u03b22 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer","volume":"33","author":"Renz","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2019.03.010_bib0090","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2019.03.010_bib0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcp.25092","article-title":"Selective \u03b22-ar blockage suppresses colorectal cancer growth through regulation of EGFR-Akt\/ERK1\/2 signaling, G1-phase arrest, and apoptosis","volume":"231","author":"Chin","year":"2016","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1126\/science.aah5072","article-title":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","volume":"358","author":"Zahalka","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.drudis.2019.03.010_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/onc.2015.58","article-title":"\u03b22-AR signaling controls trastuzumab resistance-dependent pathway","volume":"35","author":"Liu","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2019.03.010_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.055","article-title":"\u03b22-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction","volume":"665","author":"Shan","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","author":"Tang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0120","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic \u03b2-blocker use and lung cancer survival: a population-based cohort study","volume":"7","author":"Weberpals","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.03.010_bib0125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","article-title":"Meta-analysis of the effects of beta blocker on survival time in cancer patients","volume":"140","author":"Choi","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","article-title":"Beta blockers and cancer prognosis \u2013 the role of immortal time bias: a systematic review and meta-analysis","volume":"47","author":"Weberpals","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drudis.2019.03.010_bib0135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"\u03b2-blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.drudis.2019.03.010_bib0140","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drudis.2019.03.010_bib0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.drudis.2019.03.010_bib0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol use is associated with reduced cancer risk: a nationwide population-based cohort study","volume":"184","author":"Lin","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2019.03.010_bib0160","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2004.02.027","article-title":"The risk of cancer in users of statins","volume":"22","author":"Graaf","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jphp.12707","article-title":"Statins anticancer targeted delivery systems: re-purposing an old molecule","volume":"69","author":"Safwat","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0170","first-page":"2223","article-title":"Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells","volume":"5","author":"Agarwal","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2019.03.010_bib0175","first-page":"2067","article-title":"Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin","volume":"7","author":"Wong","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2019.03.010_bib0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/carcin\/22.8.1139","article-title":"Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study","volume":"22","author":"Denoyelle","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drudis.2019.03.010_bib0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.13105\/wjma.v5.i2.41","article-title":"Statin use and risk of cancer: an overview of meta-analyses","volume":"5","author":"Undela","year":"2017","journal-title":"World J. Meta-Anal."},{"key":"10.1016\/j.drudis.2019.03.010_bib0190","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.03.010_bib0195","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/154099903322447710","article-title":"Lipid-lowering drug use and breast cancer in older women: a prospective study","volume":"12","author":"Cauley","year":"2003","journal-title":"J. Women\u2019s Health"},{"key":"10.1016\/j.drudis.2019.03.010_bib0200","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/joim.12806","article-title":"Statins: a role in breast cancer therapy?","volume":"284","author":"Borgquist","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.drudis.2019.03.010_bib0210","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/djr291","article-title":"Statin prescriptions and breast cancer recurrence risk: a danish nationwide prospective cohort study","volume":"103","author":"Ahern","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drudis.2019.03.010_bib0215","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ijc.30185","article-title":"Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis","volume":"139","author":"Manthravadi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2019.03.010_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-017-4246-0","article-title":"The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis","volume":"164","author":"Liu","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drudis.2019.03.010_bib0225","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ctrv.2015.04.005","article-title":"Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"41","author":"Zhong","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drudis.2019.03.010_bib0230","first-page":"5363","article-title":"Clinical potential of statins in prostate cancer radiation therapy","volume":"37","author":"Hutchinson","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drudis.2019.03.010_bib0235","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2010.10.003","article-title":"A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells","volume":"149","author":"Kopecka","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.010_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jddst.2016.01.004","article-title":"Pravastatin-loaded chitosan nanoparticles: formulation, characterization and cytotoxicity studies","volume":"32","author":"Badran","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0245","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1538-7836.2007.02427.x","article-title":"The effect of low-molecular-weight heparin on cancer survival: A systematic review and meta-analysis of randomized trials","volume":"5","author":"Lazo-Langner","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2019.03.010_bib0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5114\/pr.2015.54034","article-title":"Administration of low molecular weight heparins for prolonging the survival of patients with cancer","volume":"2","author":"Majewski","year":"2015","journal-title":"Phlebol. Rev."},{"key":"10.1016\/j.drudis.2019.03.010_bib0255","doi-asserted-by":"crossref","first-page":"76","DOI":"10.54987\/jobimb.v2i2.160","article-title":"Beyond anticoagulant: heparin as a potential anti-cancer agent","volume":"2","author":"Lokwani","year":"2014","journal-title":"J. Biochem. Microbiol. Biotechnol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0260","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00432-016-2131-6","article-title":"Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms","volume":"142","author":"Zhang","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0265","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2019.03.010_bib0270","article-title":"Parenteral anticoagulation in ambulatory patients with cancer","volume":"9","author":"Akl","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2019.03.010_bib0275","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0280","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jth.12595","article-title":"The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials","volume":"12","author":"Sanford","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2019.03.010_bib0285","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/molecules22111932","article-title":"Anticancer and immunogenic properties of cardiac glycosides","volume":"22","author":"Schneider","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2019.03.010_bib0290","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mito.2012.06.003","article-title":"Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides","volume":"13","author":"Cerella","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1016\/j.drudis.2019.03.010_bib0295","first-page":"2141","article-title":"Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells","volume":"31","author":"Wang","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drudis.2019.03.010_bib0300","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1021\/np900210m","article-title":"Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs","volume":"72","author":"Felth","year":"2009","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.drudis.2019.03.010_bib0305","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11033-011-0908-x","article-title":"Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK","volume":"39","author":"Gao","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.drudis.2019.03.010_bib0310","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003807","article-title":"Cardiac glycosides exert anticancer effects by inducing immunogenic cell death","volume":"4","author":"Menger","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2019.03.010_bib0315","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF02256539","article-title":"Cardiac glycosides induce resistance to tubulin-dependent anticancer drugs in androgen-independent human prostate cancer","volume":"9","author":"Huang","year":"2002","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.drudis.2019.03.010_bib0320","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.taap.2009.07.026","article-title":"Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1\u03b1 in human colon cancer cells","volume":"240","author":"Riganti","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2019.03.010_bib0325","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ijc.30520","article-title":"Cardiac glycosides and breast cancer risk: a systematic review and meta-analysis of observational studies","volume":"140","author":"Karasneh","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2019.03.010_bib0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.2016.328","article-title":"Digoxin and prostate cancer survival in the finnish randomized study of screening for prostate cancer","volume":"115","author":"Kaapu","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drudis.2019.03.010_bib0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178611","article-title":"Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies","volume":"12","author":"Osman","year":"2017","journal-title":"PLoS One"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461830535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461830535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:39:18Z","timestamp":1761223158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964461830535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S135964461830535X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.010","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}